COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

The Effect of BiosLife on Serum Lipids

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00457756
Recruitment Status : Completed
First Posted : April 6, 2007
Last Update Posted : May 8, 2008
Unicity International
Information provided by:
University of Utah

Brief Summary:
This is a double-blind, placebo-controlled study to assess the effectiveness of BiosLife in lowering serum LDL cholesterol and raising HDL cholesterol. BiosLife is a natural supplement (mixed in water and taken twice daily) which contains guar gum and other natural soluble fibers, phytosterols, policosanol, and a proprietary chrysanthemum extract. Approximately 100 subjects with baseline LDL cholesterol of 110-190 mg/dL will be randomized in a 2:1 ratio to BiosLife or a look-alike placebo. Changes in lipids from baseline will be assessed at 6 weeks and 12 weeks.

Condition or disease Intervention/treatment Phase
Hypercholesterolemia Dietary Supplement: BiosLife Complete Dietary Supplement: Placebo Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 100 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: The Effect of an Integrative Dietary Supplement on the Lipid Profile of Subjects With Hypercholesterolemia
Study Start Date : January 2007
Actual Primary Completion Date : July 2007
Actual Study Completion Date : July 2007

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Active Comparator: I
Cohort I subjects will take supplement for 12 weeks
Dietary Supplement: BiosLife Complete
Placebo Comparator: II
Cohort II will take placebo for 12 weeks
Dietary Supplement: Placebo

Primary Outcome Measures :
  1. LDL cholesterol [ Time Frame: 12 weeks ]
  2. HDL cholesterol [ Time Frame: 12 weeks ]

Secondary Outcome Measures :
  1. triglycerides [ Time Frame: 12 weeks ]
  2. LDL particle number [ Time Frame: 12 weeks ]
  3. LDL particle size distribution [ Time Frame: 12 weeks ]
  4. HDL particle number [ Time Frame: 12 weeks ]
  5. HDL particle size distribution [ Time Frame: 12 weeks ]
  6. VLDL particle number [ Time Frame: 12 weeks ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 85 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • LDL-C 110 - 190 mg/dL
  • For current lipid-lowering prescription therapy users, the dose of lipid-lowering medication must have been constant for 3 months with no current plan for change in dose.
  • Age 18 - 85 years

Exclusion Criteria:

  • Type 1 diabetes
  • Severe hypertension, defined as at least 180 / 100 mmHg
  • Any other health condition that may interfere with the study results, as judged by the principle investigator
  • Allergy against any of the ingredients in the tested product
  • Any medical condition, in which fiber consumption is contraindicated (e.g. Crohn's disease
  • The use of nutritional supplements during the last two months containing one or more similar ingredients, as the tested supplement.
  • History of alcohol or drug abuse, psychological or other mental issues that are likely to invalidate informed consent, or limit the ability of the patient to comply with the protocol requirements
  • Participation in any other studies involving investigational or marketed product concomitantly or within one month prior to entry into the study
  • Pregnant or breast feeding
  • Persons who eat only 1 meal per day

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00457756

Layout table for location information
United States, Utah
Cardiovascular Genetics, University of Utah, 420 Chipeta Way, Room 1160
Salt Lake City, Utah, United States, 84108
Sponsors and Collaborators
University of Utah
Unicity International
Layout table for investigator information
Principal Investigator: Paul N Hopkins, MD, MSPH University of Utah
Layout table for additonal information
Responsible Party: Paul Hopkins, MD, MSPH, University of Utah Identifier: NCT00457756    
Other Study ID Numbers: BiosLife 2005-4
First Posted: April 6, 2007    Key Record Dates
Last Update Posted: May 8, 2008
Last Verified: May 2008
Keywords provided by University of Utah:
LDL cholesterol
HDL cholesterol
natural supplement
guar gum
Additional relevant MeSH terms:
Layout table for MeSH terms
Lipid Metabolism Disorders
Metabolic Diseases